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Abstract: Under stress conditions, the metabolic demand for nutrients increases, which, if not met,
may slow down or indeed stop the wound from healing, thus, becoming chronic wounds. This
study aims to perform a systematic review and meta-analysis of the effect of arginine and glutamine
supplementation on wound healing. PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines were followed for the systematic review and ten electronic databases were
used. Five and 39 human studies met the inclusion criteria for arginine and glutamine, respectively.
The overall meta-analysis demonstrated a significant effect of arginine supplementation on hydrox-
yproline content (MD: 4.49, 95% CI: 3.54, 4.45, p < 0.00001). Regarding glutamine supplementation,
there was significant effect on nitrogen balance levels (MD: 0.39, 95% CI: 0.21, 0.58, p < 0.0001), IL-6
levels (MD: −5.78, 95% CI: −8.71, −2.86, p = 0.0001), TNFα levels (MD: −8.15, 95% CI: −9.34, −6.96,
p < 0.00001), lactulose/mannitol (L/M) ratio (MD: −0.01, 95% CI: −0.02, −0.01, p < 0.00001), patient
mortality (OR: 0.48, 95% CI: 0.32, 0.72, p = 0.0004), C-reactive protein (CRP) levels (MD: −1.10, 95%
CI: −1.26, −0.93, p < 0.00001) and length of hospital stay (LOS) (MD: −2.65, 95% CI: −3.10, −2.21,
p < 0.00001). Regarding T-cell lymphocytes, a slight decrease was observed, although it failed to
reach significance (MD: −0.16, 95% CI: −0.33, 0.01, p = 0.07). Conclusion: The wound healing might
be enhanced in one or at various stages by nutritional supplementation in the right dose.
Keywords: arginine; collagen deposition; contraction; food; glutamine; growth factor; gut permeabil-
ity; interleukin; re-epithelialization; wound healing
1. Introduction
A wound is known as the disruption in the physical continuity of functional tissues [1–4].
The healing process begins immediately after an injury [5–8] and involves four phases [3,9–13].
The healing process consists of a series of sequential and overlapping physiological phases
or stages that can persist for years [9,14–17], as shown in Figure 1. It is not a linear process
and, depending on diverse extrinsic and intrinsic factors, such as growth factors and
cytokines, it can progress both backward and forward through the stages.
1.1. Nutrition
Nutrition is recognized as a key factor in wound healing. Under conditions of stress
such as trauma or after surgery, the nutritional demand is increased [18–20] in part due to
cell proliferation and protein synthesis [21].
Arginine is a conditionally essential amino acid that is synthesized from citrulline in
healthy humans [22] (Figure 2). Based on previous reviews, arginine has been shown to
modulate the immune function, hormone secretion, and endothelial function as well as
being a precursor to the synthesis of proline in animal and human trials [23–25].
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nithine is transformed into proline, which is needed for collagen synthesis. L-ornithine can also be 
converted to polyamines, which are required for cell proliferation by ornithine decarboxylase [22]. 
There are two pathways in wound healing involving arginine (a) the arginase path-
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.
i i e can be catabolized via the NO synthase pathway. Here, L-Arginine ca be converted
to L-ornithine and urea by arginase I. Then, by the action of ornithine aminotransferase, ornithine is
transformed into proline, which is needed for collagen synthesis. L-ornithine can also be converted
to polyamines, which are required for cell proliferation by ornithine decarboxylase [22].
There are t o pathways in wound healing involving arginine (a) the arginase pathway,
hich produces polyamines, as well as ornithine and proline. Polyamines are needed for
c ll proliferation, while the latter ones are required for th synthesis of collagen; and (b) the
inducible nitric oxide (NO) synthetase or iNOS pathway, which is a precursor of nitric
oxide (Figure 2). NO plays a key role in wound healing as it regulates cell proliferation,
collagen formation, and wound contraction [22,26].
Glutamine is the m st abundant ami o aci f und in human blood plasma. It is used
as a source of energy for the cells to proliferate, including l mphocytes, macrophages,
fibroblasts, and epithelial cells [21,23]. Similar to arginine, its concentration in plasma de-
creases under conditions of metabolic stress, such as injury, and its depletion is proportional
to the acuteness f th traum [27–30].
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Some studies have demonstrated that glutamine enhances wound healing, in part,
because it increases the concentration of arginine and citrulline, a precursor of arginine
(Figure 3). Glutamine thus allows the production of NO in the absence of extracellular
arginine in monocytes and macrophages [28,31–34]. This amino acid also reduces gut
atrophy [35–39] and limits intestinal permeability [40–46], indirectly reducing the pro-
duction of proinflammatory cytokines [47]. The intestinal permeability, measured by the
lactulose/mannitol excretion ratio, is an important parameter in wound healing since
its increment is correlated with the production of proinflammatory cytokines, such as
interleukin-6 (IL-6) [48] which plays a key role in the modulation of healing through the
regulation of differentiation, activation, and proliferation of keratinocytes, leukocytes,
fibroblasts and endothelial cells [49]. Glutamine has also been shown to reduce C-reactive
protein (CRP). CRP plays important roles in inflammatory processes and hosts reactions
against infections, including NO release, apoptosis, and the production of IL-6 and tumor
necrosis factor-α (TNFα). Therefore, CRP levels increase in sick patients and are correlated
with the severity of the illness in the patient, thus, objectively quantifying the patient’s
stress and acuity [50,51]. Hence, the decline of CRP indicates the reduction of the overall
inflammation. Glutamine also acts as an antioxidant through the production of glutathione
(GSH) [29,52].
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by the action of ASS and ASL, respectively. Arginine can then be turned into nitric oxide or ornithine. Ornithine can be
transformed into glutamine, and vice versa, via glutamate and pyrroline-5-carboxylate.
1.2. Why It Is Important to Do This Review
Both arginine and glutamine are considered conditionally essential amino acids. There-
fore, they are needed in stress conditions and thus, for wound healing to occur. There is
existing information suggesting their mechanism of action in the different stages of healing.
However, it is our belief that no previous systematic review and meta-analysis has been
conducted on arginine supplementation and its effect on wound healing. In the case of
glutamine, its beneficial effect on hospital stay has been reported by two meta-analyses
performed by Bollhalder et al. [53] and Novak et al. [54]. However, the first review only
included enteral supplementation and focused on the length of hospital stay and mortality.
Whereas the second one focused on surgery and critically ill patients. To our knowledge,
there is currently no evidence of the effect of their supplementation on different variables
affecting wound healing.
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This systematic review and meta-analysis aimed to evaluate the effect of supplemen-
tation of arginine or glutamine on wound healing or parameters related to healing.
2. Materials and Methods
The following systematic review was performed according to the Preferred Report-
ing Items for Systematic Review and Meta-Analysis (PRISMA) statement [55]. Furthermore,
this review follows the Population, Intervention, Comparison, and Outcome
(PICO) characterization.
2.1. Search Strategy
The databases searched for relevant papers published before October 2020 were
Pubmed, American Physiological Society Publications, Taylor & Francis Online, Web of
Science, EMBASE, grey literature research with Google Scholar.
Based on the search strategy, the following keywords and synonyms/medical subject
headings were used: arginine or glutamine and (inflammation or healing or wound or
surgery or cytokines or interleukin or nutrition or hospital stay or C-reactive protein).
Words were combined using Boolean operators (OR/AND) (Table 1). References from
pertinent articles were also examined for additional studies. Searches were conducted and
data from the selected articles were extracted by one researcher (E.A.L.) and cross-checked
by another researcher (NZ). For the meta-analysis data, the authors of the selected articles
were contacted for the original data when needed.
Table 1. Search terms and search strategy.
Patient/Population Intervention Outcome Study Designs Combining SearchTerms
Patients Amino acid Randomizedcontrolled trial
Patients undergoing








Healing OR Wound OR
Cytokines OR Interleukin











Inclusion criteria: studies selected were randomised controlled trials (RCTs) where
patients above 18 years old, healthy or not, suffering from acute or chronic wounds were
supplemented with arginine or glutamine (Figure 4 and Figure 5).
Exclusion criteria: Studies that did not entail in vivo human studies involving supple-
mentation with arginine or glutamine were excluded from the review. Studies involving
participants below 18 years of age were excluded from the review due to the metabolic
stress already occurring resulting from growth. Studies involving patients with diabetes,
where data were not complete or the original data were not presented and studies in
another language other than English, Spanish or French were excluded from the review.
2.2.1. Population
Adults above 18 years old, healthy or not, suffering from acute or chronic wounds.
2.2.2. Intervention
Diet supplemented with either arginine or glutamine for at least 5 days.
2.2.3. Comparator
A control group, either treated with a placebo or not treated.




Figure 4. Flow diagram of the search strategy for arginine. 
 
Figure 5. Flow diagram of the search strategy for glutamine. 
  
Figure 4. Flo diagra of the search strategy for arginine.




         i i . 
 
Fig re 5. Flo  iagra  of t e searc  strategy for gl ta i e. 
  
Figure 5. Flow diagram of the search strategy for glutamine.
Nutrients 2021, 13, 2498 6 of 26
2.2.4. Outcomes
The outcomes included in the meta-analysis were: nitrogen balance (g N), hydrox-
yproline content (nmol/cm), T-cell lymphocytes levels, tumour necrosis factor-α (TNFα)
levels (pg/mL), C-reactive protein (mg/dL), intestinal permeability (L/M ratio), length of
hospital stay (LOS) (days), patient mortality (deaths), IL-6 levels (mg/dL).
2.3. Data Extraction and Management
Data for the meta-analysis were extracted from figures using WebPlotDigitizer [56],
tables and the test from the articles, and the change in mean and standard deviation
between the baseline and final values for each outcome were used for the meta-analysis.
No publication date restrictions were applied. Units of measurements were converted to
mg/dL for CRP as necessary. Additionally, median values were converted to means and
1st–3rd quartiles were transformed into standard deviations, respectively.
2.4. Quality Assessment
The risk of bias assessment was assessed by the Cochrane risk of bias tool [57]. The
domains evaluated included the random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and personnel (performance bias),
blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias),
selective reporting (reporting bias), and other bias. Low risk of bias is indicated by a plus
(+), unclear risk of bias by a question mark (?), and high risk of bias by a minus (−).
2.5. Data Analysis
Changes from baseline for the intervention were compared with the control in all
the parameters analyzed [57]. The pooling of the data was conducted with the meta-
analytic methodology, utilizing Cochrane Review Manager 5.4.1 (2020) [58] for the different
outcomes evaluated applying fixed effects, the mean differences (MDs) and odds ratio as a
degree of effect extent. Nevertheless, for nitrogen balance and T-cell lymphocytes levels,
data were converted into standardized mean difference (SMD) owing to the use of different
measurement scales. Pooled effect size estimates are presented with their 95% confidence
intervals (95% CI). When studies reported multiple results (i.e., multiple-dose), these were
included in the meta-analysis as independent comparisons. Heterogeneity was assessed
using I2 and Chi2 and considered significant when I2 > 50%. Results were considered
significant when the p-value was below 0.05.
3. Results
Five (5) and 39 studies on arginine and glutamine, respectively were included in the
systematic review (Figures 4 and 5) (Tables 2 and 3).
3.1. Assessment of Risk of Bias of Included Studies
3.1.1. Risk of Bias of Included Studies on Arginine
The risks of bias in the included studies are shown in Figure 6. 100% of the studies
showed a low risk of bias in relation to the random sequence generation and allocation
concealment. While less than 75% have demonstrated a low risk of bias with respect
to blinding of participants and personnel. In terms of blinding of outcome assessment,
incomplete outcome data and selective reporting, all the studies showed a low risk of bias
except for Barbul et al. [59] which exhibited an unclear risk of bias. Regarding other risks of
bias, less than 50% of the studies showed a low risk of bias whereas the Langkamp-Henken
study [60] demonstrated a high risk of bias.
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3.1.2. Risk of Bias of Included Studies on Glutamine
The risks of bias in the included studies are shown in Figure 7. Of the studies, 10 %
showed a low risk of bias in relation to the random sequence generation. All the studies
have demonstrated a low or unclear risk of bias regarding blinding of participants except
the Goeters et al. [61] and Xian-Li et al. [62] studies, which exhibited a high risk of bias.
On the other hand, more than 50% of the studies showed an unclear and high risk of bias
in terms of other biases. The high bias is the case of Engel et al. [63] and Goeters et al.
studies [61]. With respect to the other risk of bias, more than 75% of the studies exhibited
a low risk of bias regarding allocation concealment, blinding of outcome assessment,
incomplete data and selective reporting.
3.2. Effects of Interventions
Based on the systematic review and meta-analysis, one distinct area was identified
under arginine: Collagen deposition (hydroxyproline content); and seven distinct areas
were identified under glutamine: nitrogen balance; wound healing time; length of hospital
stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6
levels, TNFα levels) and T-cell lymphocytes.
3.3. Arginine (Arg)
Research on the pharmacological effects of arginine supplementation has been mostly
based on its use for acute wounds, although some trials have studied its effect on chronic
wounds (Table 2).
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Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported outcomes.
Study Duration PatientPopulation n Dosage Control Group Outcome
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Debats et al. [65] 5 days Surgery 35 30 g intravenousArg
Isonitrogenous
solution
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137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartat  (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
tro s). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, ran omly supplemented or not with 17 g of arginine per 
ay for 14 days. An improvement was also observed in collage  synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
ti n. 
Argi ine also influences the nitrogen b lance. Nev rtheless, this balance improve-
ment has b en reported in many, bu  not in all studies. In a ra domized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
m a ured aft r supplementing 30 g of arginine (n = 16) or pla ebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels p r high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
Angiogenesis,
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were identified u der glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; actulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
R se rch on the pharmacological effects of arginine supplementation has been 
mostly based on its us for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study D ration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposi io , ↑




14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Iso itrogenous 
solution 
↔ Citrulline, or ithin  and 
NO levels, ↔ Ang ogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
La gkamp-
Henken et al. 
[60]
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expe diture; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have d monstrated that suppl m ntation with arginine increases col-
l gen eposition a d, ther fore, enhances wound-breaking treng h. The wound-break-
ing s rength is the force needed t  disrupt a wound [67]. Barbul et al. [59] observed t is 
i prov ment in a randomized, controlled trial (RCT) in 36 healthy and on-smoking hu-
mans by suppl menting t eir diet with 24.8 g fr e arginine as arginine h d chloride 
a d 17 g of free argini e as argin ne aspartate p r day f r 2 weeks. Hydroxyproline c n-
te t was ass ssed as an index of the synthesis and deposition f new collagen in a poly-
tetrafluoroethylene tube i serted in the wound site. An enhanced colla en deposition at 
137 and 74% was noted in the a ginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arg ni e aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respect vely, foll wing a sig-
nificant diff rence observed i  the controlled gro p (p < 0.001; 10.1 ± 2.32 nm l/cm in con-
trols). Thes  resul s were c nfirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly suppl m nted or not with 17 g of arginine per 
day f r 14 days. An improvement was also observed i  collagen synth sis through the 
hydroxyproline depositio  (17.4 ± 2 nmol/cm; p < 0.02) and T- ll- ediated immune func-
tion. 
Arginin so influences the nitrogen b l nce. Nevertheless, this balance improve-
me t has been reported in many, but not in ll studi s. In  randomized double-blind 
controll study by D bats et al. [65], specific parameters related to wound healing were 
measured after suppl menting 30 g of arginin  (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
Reepithelialisation
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were identifi d under glutamine: itrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacolo ical effects of rgini e s ppleme tation has been 
mostly based on its use for acute wounds, alth ugh some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte itogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
p essure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydr xy-β-m th lbutyrate; IGF-1: insul n-like growth facto ; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies hav  demonstrated that suppleme ation with arginine incre ses col
lagen depositio  a d, the efor , enh nc s w und-break ng strength. T  wound-break-
ing strength is the force n ded o disrupt  wound [67]. Barbul et a . [59] observe  this 
improv men  i  a r ndomiz , controlled trial (RCT) i  36 h alth  nd non-smoking hu-
mans by supplementing t eir diet with 24.8 g of fr e arg ine as argini e hy rochl ride 
and 17 g of fr e arginin  as rginine aspa ate per day f  2 weeks. Hydr xyproline con-
te t was assessed as an index of the synthesis a d deposition of new collagen in a poly-
tetrafluoro thylene tube i sert  in th  wound site. An enhanced collagen d position at 
137 and 74% was noted in th  arginine hydrochl ride (p = 0.028; 23.85 ± 2. 6 nmol/ m) and 
arginine spa t te (p = 0.028, 17.57 ± 2.16 mol/cm) groups, respectiv ly, foll ng a sig-
nificant d ff rence observed in the c ntrolled group (p < 0.001; 10.1 ± 2.32 n ol/cm i  con-
trols). These results were confirmed later by Nussb u  [64], who carried out a similar 
trial in 45 healthy e d ly people, randomly supplemented or no  with 17 g of arginin  per 
day for 14 days. n improveme t was also obse ved i  collagen synthesis through the 
hydroxyprolin  depo ition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-m dia ed immun  func-
tion. 
Arg nine als  influence  the nitrog  balance. Nevertheless, thi  balance improve-
m nt has been reported in many, but n t i  all studies. In a rand mized doubl -blind 
controlled study by D bats et al. [65], pecific param te s related to wound h aling were 
measured after supplementing 30 g of arginine (  = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
Lymphocyte
proliferation,
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were id ntified under glutamine: itrogen balance; wound healing time; length of hospi-
tal stay and patient m rtality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymph cytes. 
3.3. Arginine (Arg) 
Research n the pharmacological effects of arginine supplem ntation has been 
mostly b sed on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barb l et l. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition,  
Wound-breaking stre gth, 
↑ Lymph cyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
m ted 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
 Citrulline, ornithine and 
NO l ve s, ↔ Angiogenesis, 
 Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 week  
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: cop er; Gln: glutamine; HBM: β- ydr xy-β-methylbutyrate; IGF-1: insulin-l ke growth factor; NO: ni-
tric oxide; P: pho phorous; RME: res ing m tabolic expendi ure; Zn: zinc; ↑: increases; ↔ does ot increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several tudi s h ve demonstra ed t at suppl m t tion with argi ine i creases c l-
lage  dep ition and, herefore, e hances wou d-b akin  str gth. The wound-break-
ing strength i  th  for e ed  t  disrupt a woun [67]. Barbul t al. [59] bs rved this 
im r v me t in a ra dom zed, c n r lled rial (RCT) in 36 healt  and non-smok g hu-
m ns by supplem ti g their diet with 24.8 g of fr  argini e as argini  hydrochloride 
a d 17 g of free arginine as arginine s artate per day for 2 weeks. Hydroxypr line con-
t nt was assessed as an index of t e y thesis and deposition f n w co l gen in a poly-
tetrafluo o thyl e tu e i s rted in the w un  site. An enhanced collagen depositio at 
137 and 74% w s not d in the arg nin  hydro hlorid  (p = 0.028; 23.85 ± 2. 6 nm l/cm) and 
arginin  aspart e (p = 0.028, 17.57 ± 2.16 nmol/ m) groups, respectiv l , foll wing a sig-
nificant diffe en  observed in the controlled gr up (p < 0.001; 10.1 ± 2.32 n ol/c  in con-
trols). These r ults we e c nfirmed later by Nus baum [64], who ca ried out a similar 
tri l i  45 healthy elderly p ople, randomly supp emented or not with 17  of rginine per 
day for 14 days. An improvement was als  o serv d in collag n ynth sis thr gh the 
hydroxyprolin  eposition (17.4 ± 2 mol/cm; p < 0.02) and T-c l-me iated immune func-
tion. 
Argini  also influe ces t itrogen bala c . Neverthel ss, this balance mprove-
ment has be n reported in many, but ot in all studi s. In a random zed d ble-blind 
cont olle  study by Debats et al. [65], specific pa amet rs related to woun  healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assess d as the number of vessels p r high power field significantly in-
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were id n ified under glutamine: nitrogen balance; wound he ling tim ; length of hospi-
tal stay a  patient mo tality; l ctulos / annitol r io; C-reactive protein; cytokines (IL-6 
levels, TNFα leve s) and T-cell lymphocytes. 
3.3. Arginine (Arg)
Research on th  pharmacological effects of arginine supplementation has been 
mostly based on its use for acut  wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
 Collagen d positi n,  
Wound-breaking stre gth, 
↑ Lymphocyte itoge sis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
ment d 
↑ Collagen synthesis, ↑ T-
cell-mediated immune fu c-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogen s s, 
↔ Reepithelialisation 
Sigal et al. 
[66] 
7 days Abdominal surgery 30 14.7 g intravenous Arg 
Isonitrogenou
olution 
↔ Lymphocyt  prolifera-
tio , ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbuty ate; IGF-1: insulin-l ke g owth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic exp nditure; Zn: zinc; ↑: increases; ↔ does ot increase o  decre se. 
Collagen D positio  (Hydroxyproline Co tent)0892 
Several stu i s have de o strat d that suppl mentation with arginine increas s c l-
lagen deposition and, ther fore, nha ces wound-breaking strength. The wound-break-
ing strength is the force eeded t  disrupt a woun  [67]. B rbul et al. [59] observed this 
improvement in a randomized, con rolle  trial (RCT) in 36 healthy and non-smoking hu-
mans by suppleme ting their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free rginine as rginine aspartat  per day for 2 eeks. Hydroxyproline con-
tent was assesse  as an index of the ynthesis and depositi n of n w collagen in a poly-
tetrafluoroethylene tube inser e  i  t  wound site. An enhanced collage  depositio  at 
137 and 74% w s oted in t e arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 n ol/cm) groups, r s ctively, following a sig-
nificant difference obse ved in th  controlled group (p < 0.001; 1 .1 ± 2.32 nm l/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a simila  
trial in 45 healthy elderl  people, rando ly supplemented o  not ith 17  of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis thr ugh the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine als  influences th  nitroge  balance. Ne rtheless, t is balance improve-
ent has been reporte  in many, but not in all studies. In a randomiz  double-blind 
controlled study by Debat  et al. [65], specific par meters related to wound healing were 
measured after supplementing 30 g of arginin  (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels pe  high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
Lymphocyte
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were identified under glutamine: itroge balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-react ve prot in; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research  the pharmacolo ical effects of arginine supplem ntation has been 
mostly b sed on its use for acute wounds, although some trials have studied its ffect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect f arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosa e Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not suppl -
mented 
 Collagen d p sition, ↑ 
Wound-br aki g stren th, 
↑ Lymphocyte itogen sis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ C llage  synthesis, ↑ T-
cell-mediated immune fu c-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous r  
Isonitrogenous 
solution 
 Citrulline, ornithine and 
NO l ve s,↔ Angiogenesis, 
↔ Re pithelialisation 
Sigal et al. 
[66] 
7 days Abdominal surgery 30 14.7 g intravenous Arg 
Ison trogenou  
s lution 
↔ Lymphocyte prolifera-
tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphoro s; RME: resting metabolic expenditur ; Zn: zinc; ↑: increases; ↔ does not incre se or decrease. 
Coll gen Deposition (Hy roxy roline Content)0892 
Several studies have demonstrated that supplem tation with arginine increases col-
lagen d p sition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the for e need d to disrupt a wound [67]. Barbul et al. [59] observed this 
im roveme t in a randomized, contr lled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementi g their diet with 24.8 g of fre  arginine as argini  hydrochloride 
and 17 g of free arginine as arginine spartate per day for 2 weeks. Hydroxyproline con-
t nt was assessed as an index of the synthesis a d deposition of new collagen in a poly-
tetrafluoro thylen  tube i serted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginin  aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 n ol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
tri l in 45 healthy elderly people, randomly supplemented or not with 17  of arginine per 
day for 14 days. An improvement was also observ d in collagen synth sis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the itrogen balance. Nevertheless, this balance improve-
ent has been reported in many, but not in all studies. In a randomized double-blind 
cont olled study by Debats et l. [65], specific pa amet rs related to woun  healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
NO,
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/ annitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effect  of arginine supplementation has be n 
mostly based on its u e for acute wounds, although some trials have studied its ff ct on 
chronic wo ds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcom
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not suppl -
mented 
↑ Collagen eposition, ↑ 




14 days Surgery 30 17  Arg 
Not suppl -
me ted 
↑ C llagen synthesis, ↑ T-
cell-mediated immu e func-
ti n, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surg y 35 30 g intravenous Arg 
Isonitrogeno s 
solution 
 Citrulline, ornithin  and 
NO l vels, ↔ Angiogene is, 
 Re pithelialis ti n
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insuli -like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposi i n (Hy roxyproline Cont nt)0892 
Several studies have demonstrat d that supplementation with arginine increases col-
lagen deposition and, therefore, nhances wound-breaking strength. The wound- r ak-
ing strength is the force nee ed to isrupt a wound [67]. Barbul et l. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of fr e a ginine as arginine h chloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and depositio  of new collagen i  a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% w s noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 n ol/cm) a d 
argini e aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) r s, respectively, following a sig-
nificant difference ob erved in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, rando ly supplemented or not with 17 g of arginine per 
day for 14 da s. An impr vement was also bserved in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Argi ine also i fluences the nitrogen balance. Neverth less, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats t al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the numb r of vessels per high power fi ld significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-2
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: nitric oxide;
P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases;
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactul se/man itol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its ffect on 
chronic wo nds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control G oup Outcom  
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
N t supple-
e ted 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not sup -
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune fu c-
tio ,  IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 
33 0, 8.5 or 17 g Arg 
Not supple-
e ted 
↔ Lymph c t pr lif ra-
t o , ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gl : glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Conte t)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
does not increase or decrease.
Collagen Deposition (Hydroxyproline Content)
Several studies ave demonstrat d that supplementatio with argini e i reases col-
lagen deposition and, therefore, e hances wo nd-breaking strength. The wound-breaking
strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this im-
prove ent in a randomized, controlled trial (RCT) in 36 healthy and non-smoking humans
by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride and
17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline content
was assessed as an index of the synthesis and deposition of new collagen in a polyte-
trafluoro thylene tube inserted in the wound site. An enhanced collagen deposition at
137 a d 74% was note in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm)
and arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following
a significa t difference obse ved in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm
in controls). These r sults were confirmed later by Nussbaum [64], who carried out a
simi ar trial in 45 hea thy elderly people, randomly suppleme ted or not with 17 g of
arginine per day for 14 days. An improvem t was al o observed in collagen synthesis
through the hydroxyproline deposition (17.4 ± 2 nmol/c ; p < 0.02) and T-cell-mediated
immune function.
Arginine also influences the nitrog n balance. Nevertheless, this balance improvement
has bee reported in many, but not in all studies. In a randomized double-blind controlled
study by Debats et al. [65], specific paramet rs related to wou d healing were measured
after supplementing 30 of arginine (n = 16) or placebo ( = 19) for 10 days. Angiogenesis,
assessed as the number of vessels per high power field significantly increased on day 10
(8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). Meanwhile,
the increment in re-epithelialization failed to reach significance (85 ± 7.1% in the arginine
group vs. 81 ± 8.5% in the placebo group, p > 0.05).
In a double-blind RCT conducted and involving 30 adults for 7 days by Sigal et al. [66],
the enhancement of lymphocyte proliferation was not observed (p > 0.05) after intravenous
supplementation with 14.7 g of arginine compared to controls, treated with Travasol 10%
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(an isonitrogenous mix of amino acids). The nitrogen balance measured in the supple-
mented group (−8.8 g/day) was comparable to the control group (−9.2 g/day, p > 0.05).
Langkamp-Henken et al. [60], also conducted an RCT on 33 elderly patients supple-
mented with different amounts of arginine (0, 8.5, or 17 g) for 4 weeks. These amounts of
arginine used represented approximately 2.2 and 4.5% of an 1800 kcal intake, respectively.
The mean daily intake of the patients in this study ranged between 1713 and 2474 kcal
with an additional 2.4 and 3.3 g of arginine. After the treatment, no increase in lymphocyte
proliferation was observed between groups, while NO increased, although not statistically
significant (p > 0.05).
Effects of arginine supplementation on collagen deposition, measured by hydrox-
yproline content were reported in 2 studies. The study conducted by Barbul et al. [59]
reported two results due to two different amounts of supplementation given (17 and
24.8 g arginine). Compared to control, arginine supplementation significantly enhanced
hydroxyproline content (MD: 4.49, 95% CI: 3.54, 5.45, p < 0.00001, Figure 8). There was a
high heterogeneity (I2 = 99%) among studies. However, there was a lack of significance
between the intervention and control group in the Nussbaum study [64] (MD: −0.01, 95%
CI: −1.27, 1.25).
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ing. This behavior was confirmed by many of the randomized controlled trials that will 
be reported below, where patients with a total, partial parenteral or early enteral nutrition 
were supplemented with alanine-glutamine dipeptide, in a concentration ranging from 
0.2 to 0.5 g Ala-Gln/kg/day for up to 14 days, as summarized in Table 3. Ala-Gln dipeptide 
is usually used instead of free Gln, due to its heat stability and its rapid hydrolyzation to 
free amino acids in plasma [68]. 
Figure 8. Hydroxyproline content: fixed-effects eta-analysis and forest plot fro studies providing supplementation
of arginine.
3.4. Glutamine (Gln)
Glutamine has been shown to influence s v ral parameters invol ed in wound healing.
This be avior was confirmed by many of the randomized controlled trials that will be
reported below, where patients with a total, partial parenteral or early enteral nutrition
were sup lemented with alanine-glutamine dipeptide, in a concentration ra ging from 0.2
to 0.5 g Ala-Gln/kg/day for up to 14 days, as summarized in Table 3. Ala-Gln dipeptide is
usually used instead of free Gln, due to its heat stability and its rapid hydrolyzation to free
amino acids in plasma [68].
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Table 3. Studies evaluating the effect of glutamine supplementation on wound healing and reported outcomes.
Study Duration Patient Population n
Dosage
Control Group Outcome
Gln (g/kg BW/day) Gln Dip (g/kgBW/day Ala-Gln)
O’riordain et al. [69] 5 days Surgery 22 0.18 0.27 Isonitrogenoussolution
↑ T-cell lymphocytes,
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-2,
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tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine s pplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen dep sition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal e  al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
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tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementati n with arginine increases col-
lagen deposition and, therefore, enhanc s wound-breaking stre gth. The wound-break-
ing strength is the force needed to disrupt a w und [67]. B rbul et al. [59] observed this 
improvement in a randomized, controlled t ial (RCT) in 36 healthy and no -smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline n-
tent was assess d as an index of the synth sis and d position of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhance  collagen deposition at 
137 and 74% was noted in the rginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) g ups, respectively, following a sig-
nificant difference observ d in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine p r 
day for 14 days. An improvem nt was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Neverthele s, this balance improv -
ment has been report  in man , but not in all studi s. In a ndomized double-blind 
controlled study by D bats t al. [65], specific parameters related to wound healing were 
measured after suppl menting 30 g of argini e (n = 16) or placebo (n = 19) for 10 day . 
Angiogenesis, assessed as the number of vessels per high power field signific ntly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-6,
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were i entified under glutamine: itrogen balance; w und healing tim ; length of h spi-
tal stay and patient mortality; lactulose/ annitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacologi al e fects of arginine supplement tion has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating he effect of arginine supplementati n on wou d healing and reported 
outcomes. 
Study Dur o  atient P pulation n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen depositio , ↑ 
Wound-breaking str ngth, 
↑ Lymphocyt  mitogen  
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synth sis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Iso itrogen s 
solution 
↔ Citrull ne, ornithine and 
NO levels, ↔ Ang ogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 
7 days Abdominal surgery 30 14.7 g intravenous Arg 
Iso itrogen s 
solution 
↔ Lymphocyt  prolifera-
tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elder y people with 
pressure ulcers 
33 0, 8.5 or 17 g Arg 
Not supple-
mented 
↔ Lymph cyt  prolifera-
tion,  NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: nsulin-like growth factor; NO: ni-
tric oxide; P: pho phorous; RME: r sting m tabolic expenditure; Zn: zi c; ↑: increases; ↔ does not increas  or decrease. 
Collagen Deposition (Hydroxypr line Content)0892 
Several studies have demonstrated that suppleme tation with argi ine in r ases col-
lagen deposition and, therefore, nhances wo nd-breaking strength. The wound-break-
ing strength is th  force nee ed to disrupt a wound [67]. Barbul et l. [59] observed this 
i provement in a ran omized, controll d trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hy rochlo ide 
and 17 g of free rginine  rgi ine as a tate per day for 2 weeks. Hydroxyprolin  co -
tent was assessed as an ind x of e synthesis and dep sition of new collagen in a poly-
tetrafluoro thyl ne tub  insert d in the wound site. An nhanced collagen deposition at 
137 and 74% was not d in the arginine hydrochloride (p = 0.028; 3.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0 028, 17.57 ± 2.16 nmol/cm) s, respectively, following a sig-
nificant difference observ d i  the cont lled group (p < .001; 10.1 ± 2.32 nmol/cm in con-
trols). These results we  confirmed later by Nus baum [64], who carried out a similar 
trial in 45 health elder y people, random y suppleme t d or not with 17 g of arginine per 
day for 14 da s. An i proveme t was also observed in coll gen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also i fluences the itrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a ran omized d ble-blind 
controlled tudy by Debats et al. [65], s ecific parameters related to wound healing were 
me su ed after supplem nting 30 g of arginine (n = 16) or placebo (n = 9) for 10 days. 
Ang ogene i , assessed as th  number of vess ls per high power fi ld signif cantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
TNFα
De Beaux et al. [70] 7 days Critical illness 14 0.22 0.33 Isonitrogenoussolution ↑ Lymphocytes, ↓ IL-8,
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous rg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




ion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-6
Morlion et al. [71] 5 days Surgery 28 0.2 0.3 Isonitroge ouss lutio
↑ NO, ↓ LOS and patient
mortality, ↑Mood and general
well-being
Jacobi et al. [72] 7 days Surgery 34 0.27 0.4 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol rati ; C-reactive pr tein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wou ds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and rep rted 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 
33 0, 8.5 or 17 g Arg 
Not suppl -
men ed 
↔ Lymphocyte prolifer -
tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-10, ↑Wound healing
Jiang et al. [73] 7 days Abdominal surgery 60 0.34 0.5 Isonitrog noussolution ↑ NO, ↓ LOS
Powell-Tuck et al. [74] 4–16.5 days Mixed 168 0.26 0.38 Isonitrogeno ssolution ↓ LOS and patien mortality
Mertes et al. [75] 6 days Abdominal surgery 37 0.34 0.5 Isonitrogenoussolution ↑ NO, ↓ LOS,
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were identified under glutamine: nitro e  balance; wou d healing tim ; length of hospi-
tal stay and patient mortality; lactulose/ annitol r tio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has be  
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
s l tion 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
 Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 
33 0, 8.5 or 17 g Arg 
Not supple-
mented 
↔ Lymp ocyte pr lifera-
tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: co per; Gln: glutamin ; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Z : zinc; : increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyprolin  Conte t)0892 
Sev r l studies h ve demonstrated that supple entation with arginine increases col-
lagen deposition and, therefore, enhances w und-breaking stren th. The wound-break-
ing strength is the force neede  to disrupt a wound [67]. Barbul t al. [59] observed this 
impr vement in a ra domized, c ntrolled trial (RCT) in 36 healthy and on-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of fre  argini e as ar inine aspartate per day for 2 weeks. Hydroxyproline con-
tent was asses ed as an index of the synthesis and deposition of new collagen in  poly-
tetrafluoro thylene t be ins rted in the wound sit . An enhanced ollagen deposition at 
137 a d 74% wa  noted in the arginine hydr chloride (  = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± .16 nmol/cm) groups, respectively, f llowing a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or n t with 17 g of arginine per 
day for 14 days. An im rovement was also observed in collagen synthesis through the 
hydroxyproli e deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
IL-6
Karwowska et al. [76] 10 days Surgery 30 0.2 0.3 Isonitrogenoussolution
↑ IgA and IgG, ↑ T-cell
lymphocytes, ↓ LOS
Neri et al. [77] >7 days Surgery 33 0.2 0.3 Isonitrog noussolution ↓ LOS
Wischmeyer et al. [78] >7 days Critical illness 31 0.57 0.85 I onitrog noussolution ↓ CRP
Goeters et al. [61] >9 days Surgery 144 0.2 0.3 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing ime; length of hospi-
tal stay and patient mortality; lactulose/mannit l ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine ( rg) 
Research on the pharmacolo ical effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
T ble 2. Studies evaluating the effect of arginine supplementation on wound healing nd reported 
outcome . 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ C llagen dep sition, ↑ 
W i  str t , 
↑ Lymphocyte mitoge esis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collag n synthesis, ↑ T-
cell-mediated immu e func-
tio , ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
I onitrogenous 
solution 
↔ Citrulline, ornithi e a d 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisatio  
Sigal et al. 
[66] 




t on, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly pe ple with 
pressure ulcers 
33 0, 8.5 or 17 g Arg 
Not supple-
mented 
↔ Lymphocyte pr lifera-
tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zi c; ↑: increases; ↔ does not increase or decreas . 
Collagen Deposition (Hydroxyproline Content)0892 
Several studi s have d monstrated that supplementati n with arginine increases col-
lagen deposition a d, therefore, enhances w und-breaking strength. T e wound-break-
ing strength s the f rce needed to disrupt a wound [67]. Barbul et al. [59] observ d this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their di t with 24.8 g of free arginin  as arg nine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an ind x of the synthesis and d po ition of ne  collagen in a poly-
tetr fluoroethylene tube i serted in the wound site. An enhanced collagen deposition at
137 and 74% w  noted in the arginin  hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
a ginine asp rtate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, f llowing a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
NO, ↓ Patient morta ity
Lin et al. [79] 6 days Abdominal surgery 48 0.28 0.417 Isonit ogenoussolution
↑ NO, ↓ IL-6, ↑ T-cell
lymphocytes
Ockenga et al. [80] >7 days Critical illness 28 0.2 0.3 Isonitrogeno ssolution ↑ Lymphocytes, ↓ LOS, ↓ CRP
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Table 3. Cont.
Study Duration Patient Population n
Dosage
Control Group Outcome
Gln (g/kg BW/day) Gln Dip (g/kgBW/day Ala-Gln)
Fuentes-Orozco et al. [81] 10 days Surgery 10 0.27 0.4 Isonitrogenoussolution
↑ NO, ↓ Infectious
complications, ↑ Lymphocytes
CD4 CD8
Xian-Li et al. [62] 14 days Critical illness 69 0.27 0.4 Isonitrogenoussolution ↓ LOS and patient mortality
Zhou et al. [82] 12 days Critical illness 30 0.34 0.5 Isonitrogenoussolution
↑Wound healing, ↓ Intestinal
permeability
Quan et al. [83] 7 days Abdominal surgery 20 0.53 0.78 Not specified ↓ Intestinal permeability
Kłek et al. [84] 12 days Surgery 105 0.27 0.4 Isonitrogenoussolution ↑ Lymphocytes, ↓ LOS
Lin et al. [85] 6 days Abdominal surgery 48 0.28 0.417 Isonitrogenoussolution ↑ NO, ↓ IL-6
Yao et al. [86] 5 days Surgery 40 0.34 0.5 Isonitrogenoussolution ↓ LOS, ↑ CD14
Déchelotte et al. [87] 5 days Surgery 143 0.3 0.45 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylb yrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
LOS, ↑ NO, ↓ Intestinal
permeability
Şahin et al. [88] 10.5 ± 3.6 days Critical illness 40 0.3 0.45 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
 Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Ly phocyte itogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ ollage  synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine a d 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproli e Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
T-cell lymphocytes, ↓ LOS
Cai et al. [89] 14 days Critical illness 110 0.19 0.29 Isonitrogenoussolution ↑ T-cell lymphocytes, ↓ CRP
Duška et al. [90] 13 days Critical illness 30 0.2 0.3 Isonitrogenousso ution ↑ NO
Estívariz et al. [91] 7 days Surgery 63 0.34 0.5 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
lev ls, TNFα levels) and T-cell lymphocyte . 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
St dy Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaki g strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Deb ts et al. 
[65] 
5 days Surg ry 3  30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
N  levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyr te; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Z : zinc; ↑: increases; ↔ does not increase or ecrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrat d that supplementatio  with arginine increases col-
lagen depositio  an , ther fore, e hances woun -breaking strength. The w und-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and on-smoking hu-
mans by supplementing their di t wi h 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as argini e aspartate p r day for 2 weeks. Hydr xyproli e con-
tent was asse sed as an index of the ynthesis and eposition of new collagen in a poly-
tet afluor ethyl ne tube inserted i  the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/ m) groups, r pect vely, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nm l/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g o  arginine per 
day for 14 days. An improvement was also ob erved in collagen synthesis through the 
hydroxyproline depositio  (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
T-cell Lymphocytes,
↓ Nosocomial infections
Dong et al. [92] 6 days Abdominal surgery 40 0.35 0.5 Isonitroge oussolution
↑ T-cell lymphocytes,
↓ TNFα, ↓ IL-2R
Fuentes-Orozco et al. [93] 10 days Critical illness 44 0.27 0.4 Isonitrogenoussolution
↑ T-cell lymphocytes, ↑ IgA, ↑
NO, ↓ CRP, ↑ IL-10, ↓ IL-6
Yeh et al. [94] 7 days Surgery 70 0.2 0.29 Isonitrogenoussoluti n
↓ CRP, ↓ LOS,
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Stud  Duration Patient Population n Dosage Contro  Group O tcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
 Collagen deposition, ↑ 
Wound-bre king strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Co lagen synthesis, ↑ T-
cell-mediat d immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solu  
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ R epithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




tion, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-h droxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting me abolic expenditure; Zn: zinc; ↑: incr ases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
Patient
mortality
Asprer et al. [95] 5 dayspreoperatively Abdominal surgery 34 0.2 0.3
Isonitrogenous
s lution ↑ Lymphocytes
Nutrients 2021, 13, 2498 13 of 26
Table 3. Cont.
Study Duration Patient Population n
Dosage
Control Group Outcome
Gln (g/kg BW/day) Gln Dip (g/kgBW/day Ala-Gln)
Engel et al. [63] 3 days Surgery 58 0.5 0.74 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-reactive protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wounds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collagen deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
Not supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
solution 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔ NO 
Langkamp-
Henken et al. 
[60] 
4 weeks 
Elderly people with 
pressure ulcers 




ti n, ↔ NO, ↔ IL-2 
Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
Collagen Deposition (Hydroxyproline Content)0892 
Several studies have demonstrated that supplementation with arginine increases col-
lagen deposition and, therefore, enhances wound-breaking strength. The wound-break-
ing strength is the force needed to disrupt a wound [67]. Barbul et al. [59] observed this 
improvement in a randomized, controlled trial (RCT) in 36 healthy and non-smoking hu-
mans by supplementing their diet with 24.8 g of free arginine as arginine hydrochloride 
and 17 g of free arginine as arginine aspartate per day for 2 weeks. Hydroxyproline con-
tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
tion. 
Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
creased on day 10 (8.9 ± 3.1 in the arginine group vs. 8 ± 2.8 in the placebo group, p < 0.001). 
T-cell lymphocytes
Fan et al. [96] 7 days Abdominal surgery 40 0.13 0.2 Isonitrogenoussolution
↓ LOS and infectious
complications
Quan et al. [97] 4 days Abdominal surgery 20 0.35 0.5 Normal saline ↑ NO, ↓ IL-6
Andrews et al. [98] Up to 7 days Mixed 502 0.2 0.3 Isonitrogenoussolution
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were identified under glutamine: nitrogen balance; wound healing time; length of hospi-
tal stay and patient mortality; lactulose/mannitol ratio; C-r active protein; cytokines (IL-6 
levels, TNFα levels) and T-cell lymphocytes. 
3.3. Arginine (Arg) 
Research on the pharmacological effects of arginine supplementation has been 
mostly based on its use for acute wounds, although some trials have studied its effect on 
chronic wou ds (Table 2). 
Table 2. Studies evaluating the effect of arginine supplementation on wound healing and reported 
outcomes. 
Study Duration Patient Population n Dosage Control Group Outcome 
Barbul et al. 
[59] 
14 days Surgery 36 24.8 g Arg 
Not supple-
mented 
↑ Collag n deposition, ↑ 
Wound-breaking strength, 
↑ Lymphocyte mitogenesis 
Nussbaum 
[64] 
14 days Surgery 30 17 g Arg 
N t supple-
mented 
↑ Collagen synthesis, ↑ T-
cell-mediated immune func-
tion, ↑ IGF-1 
Debats et al. 
[65] 
5 days Surgery 35 30 g intravenous Arg 
Isonitrogenous 
sol tion 
↔ Citrulline, ornithine and 
NO levels, ↔ Angiogenesis, 
↔ Reepithelialisation 
Sigal et al. 
[66] 




tion, ↔  
Langkamp-
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Arg: arginine; Cu: copper; Gln: glutamine; HBM: β-hydroxy-β-methylbutyrate; IGF-1: insulin-like growth factor; NO: ni-
tric oxide; P: phosphorous; RME: resting metabolic expenditure; Zn: zinc; ↑: increases; ↔ does not increase or decrease. 
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tent was assessed as an index of the synthesis and deposition of new collagen in a poly-
tetrafluoroethylene tube inserted in the wound site. An enhanced collagen deposition at 
137 and 74% was noted in the arginine hydrochloride (p = 0.028; 23.85 ± 2.16 nmol/cm) and 
arginine aspartate (p = 0.028, 17.57 ± 2.16 nmol/cm) groups, respectively, following a sig-
nificant difference observed in the controlled group (p < 0.001; 10.1 ± 2.32 nmol/cm in con-
trols). These results were confirmed later by Nussbaum [64], who carried out a similar 
trial in 45 healthy elderly people, randomly supplemented or not with 17 g of arginine per 
day for 14 days. An improvement was also observed in collagen synthesis through the 
hydroxyproline deposition (17.4 ± 2 nmol/cm; p < 0.02) and T-cell-mediated immune func-
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Arginine also influences the nitrogen balance. Nevertheless, this balance improve-
ment has been reported in many, but not in all studies. In a randomized double-blind 
controlled study by Debats et al. [65], specific parameters related to wound healing were 
measured after supplementing 30 g of arginine (n = 16) or placebo (n = 19) for 10 days. 
Angiogenesis, assessed as the number of vessels per high power field significantly in-
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Patient mortality
Çekmen et al. [99] >5 days Mixed 30 0.35 0.5 Isonitrogenoussolution
↓ CRP, ↓ LOS and patient
mortality
Grau et al. [100] 5–9 days Mixed 127 0.35 0.5 Isonitrogenoussolution ↓ Nosocomial infections
Lu et al. [101] 7 days Surgery 50 0.3 0.45 Isonitrogenoussolution
↑ NO, ↓ IL-6, ↓ CRP, ↓
Infectious complications
Wernerman et al. [102] 7 days Mixed 413 0.28 0.42 Normal saline ↓ LOS and patient mortality
Xu et al. [103] 12 days Critical illness 80 Unknown Unknown Isonitrogenoussolution ↓ TNFα
Richard et al. [104] 3 days pre, 4 dayspostoperatively Surgery 22 0.53 0.78 Not supplemented
↓ LOS and patient mortality, ↓
CRP
Ala: alanine; BW: body weight; CRP: C-reactive protein; Gln: glutamine; Gln dip: glutamine dipeptide; IgA: immunoglobulin A; IL-2R: interl uki -2 receptor; IL-6: interleukin-6; LOS: length of stay; NO: nitric
oxide; TNFα: tumor necrosis factor α; ↑: increases; ↓: decreases;
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3.4.1. Nitrogen Balance
In two double-blind RCT performed in 48 patients supplemented with 0.28 g/kg/day
Gln for 6 days, by Lin et al. [79,85], higher nitrogen balance, although not significant
(−3.2 ± 1.6 vs. −6.5 ± 2.7 g N, p > 0.05) was observed after Gln treatment. Cumulative
nitrogen balance was higher in Glu-supplemented patients with lower illness severity,
assessed with APACHE II scores (acute physiology score + age points + chronic health
points), but this was not observed when severity was higher (APACHE II score > 6).
However, when compared with controls, the reducing effect was not reported, showing
that the improving effect on cumulative nitrogen balance is not due to the reduction of
muscle protein breakdown, but an enhanced protein synthesis.
In contrast, a higher cumulative nitrogen balance, adjusted to standard body surface
area, was not noted (−193 ± 50 vs. −198 ± 77 g N, p > 0.05) in a prospective double-
blind RCT conducted by Duška et al. [90], who supplemented 30 patients suffering from
critical illnesses with 0.2 g/kg/day Gln for 13 days, and compared the results against
the placebo group, treated with isonitrogenous nutrition. Similar results were reported
by Mertes et al. [75] in a double-blind RCT on 37 patients undergoing major abdominal
surgery for 5 days (−14.1 ± 9.1 vs. −31.7 ± 11.4 g N, p < 0.05). Jiang et al. [73] also noted a
rise of the cumulative nitrogen balance (144.3 ± 145.6 vs. −5.1 ± 162.7 mg/kg, p = 0.0004)
in a double-blind RCT in 60 patients undergoing abdominal surgery, supplemented with
0.34 g/kg/day or an isonitrogenous solution for 7 days.
On the contrary, in a double-blind RCT performed by Morlion et al. [71] in 28 patients
undergoing surgery, supplemented with 0.2 g/kg/day Gln for 5 days, the increase in
cumulative nitrogen balance was also observed (−7.9 ± 3.6 vs. −233.0 ± 2.6, p < 0.01).
Eleven studies reported data on nitrogen balance. Compared to control, glutamine
supplementation significantly increased nitrogen balance (MD: 0.39, 95% CI: 0.21, 0.58,
p < 0.0001, Figure 9). There was a high heterogeneity (I2 = 91%) among studies. Neverthe-
less, results reported by 3 studies lacked from significance. These studies are
Déchelotte et al. [87] (MD: 0.00, 95% CI: −0.37, 0.37), Şahin et al. [88] (MD: 0.29, 95%
CI: −0.33, 0.92), and Yeh et al. [94] (MD: 0.32, 95% CI: −0.15, 0.79).
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3.4.2. Wound Healing Time
Two trials [72,82] measured the effect of glutamine supplementation on wound heal-
ing. Zhou et l. 8 ] performed a doubl -blind RCT and noticed a lower i fection rate
(13 vs. 26%), although this difference failed to reach significance (p > 0.05). Als , it was
noted a significant reduction of the woun healing time n the study group (32.1 ± 3.3 days)
compared to he con r l group (36.6 ± 6.6 days, p < 0.012) after supplementing 30 patients
suffering from s vere burns with 0 34 g/kg/day Gln or an isonitrog nous solution, for
12 days. This data is in agreement with the RCT performed by Jacobi et al. [72] whe e,
after supplementing 34 patients with 0.27 g/kg/day Gln for 7 days, observed a signifi-
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cant increase in wound healing (p < 0.05), explained in part by the incidence of wound
complications post-surgery.
3.4.3. Length of Hospital Stay (LOS) and Patient mortality
The decrease in LOS was reported by many studies. Neri et al. [77] studied the effect
of 0.2 g/kg/day Gln in 33 patients supplemented for at least 7 days. In this trial, the study
group spent 11.5 ± 2 days hospitalized, versus the control group, which spent 15 ± 3 days
(p < 0.05). Meanwhile, in the prospective double-blind RTC carried out by Yao et al. [86]
in 40 people for 5 days, the study group spent 10.6 ± 1.2 days in the hospital, while the
non-supplemented group spent 11.7 ± 2 days (p = 0.03).
These data are in agreement with Fan et al. [96], who performed an RCT in 40 patients
undergoing surgery and observed a trend to a reduction both in LOS (22.3 ± 2.1 vs.
24.9 ± 1.7 days, p = 0.32) and infectious complications after supplementation with
0.13 g/kg/day Gln, although these data failed to reach significance. The reduction in
LOS and mortality was also observed by Wischmeyer et al. [78] in a double-blind RCT in
31 patients with severe burns, supplemented with 0.57 g/kg/day L-Gln for at least 7 days
via parenteral feeding. However, in this case, there was no significant difference seen in
the LOS (31 ± 10.1 vs. 30 ± 9.3, p > 0.05) nor mortality (1 vs. 4 deaths, p = 0.19).
Goeters et al. [61] also noticed a patient mortality decline within 6 months (11/33
vs. 21/35 deaths, p < 0.05), resulting in a 66.7% increase of survival of patients treated
for ≥ 9 days, compared to 40% in controls, in an unblinded parallel multicentre RCT in
144 critically ill patients supplemented with 0.2 g/kg/day Gln.
Despite the lack of statistical significance, Çekmen et al. [99] also observed a trend
to the reduction in LOS (19.3 ± 12.7 vs. 27.5 ± 12.1 days, p = 0.36) and patient mortality
(20 vs. 40%, p = 0.42) in a double-blind RCT in 30 critically ill patients supplemented with
0.35 g/kg/day Gln.
Karwowska et al. [76] studied the effect of glutamine supplementation and ob-
served a decrease in LOS; from 15.1 ± 3 days to 12.5 ± 1.2 days (p = 0.005) in the
supplemented group. The reduction in LOS was also seen in a double-blind RCT car-
ried out by Powell-Tuck et al. [74] in 168 patients, supplemented with 20 g Gln as part
of the nitrogen source of parenteral nutrition or standard feeds, for 7 days. The study
group spent an average of 15 fewer days in hospital, compared with the control group
(46 ± 10.7 vs. 30 ± 7.2 days, p < 0.03). The latter study failed to demonstrate a decrease in
morbidity and mortality in the study group, probably due to the younger age of the pa-
tients (48 ± 17 years old vs. 80 ± 19 years old). Nevertheless, this limitation was avoided
in a study by Xian-Li et al. [62] in a non-blinded RCT in 69 patients suffering from crit-
ical illnesses for 14 days, and it was seen, not only a reduction in LOS (25.3 ± 7.6 vs.
39.1 ± 10.6 days, p < 0.01), but also in patient mortality (0 vs. 43.5%, p < 0.01) after sup-
plementing 0.2 g/kg/day Gln. The same results were obtained by Wernerman et al. [102]
in a double-blind RCT, observing a reduction of patient mortality in ICU (8/11 vs. 14/20,
p < 0.05) after supplementing 413 patients, in ICU, with 0.28 g/kg/day Gln for 7 days.
On the other hand, Ockenga et al. [80] reported a significant reduction in LOS in
a double-blind RCT in 28 patients suffering from acute pancreatitis supplemented with
0.2 g/kg/day Gln for at least 7 days. In this trial, the LOS was an average of 4 days shorter
in the study group (21 days) compared to the control group (25 days, p < 0.05) despite the
small sample studied. In the trial conducted by Mertes et al. [75] a decrease in hospital
stay was also noted (12.8 ± 2.6 vs. 17.5 ± 6.4 days, p < 0.05) compared to the control group.
Similar results were observed by Jiang et al. [73] who noted a decrease in 4 days of LOS
(12.5 ± 5.1 vs. 16.4 ± 7.1 days, p = 0.02). Morlion et al. [71] not only noted the reduction in
LOS (15.5 ± 0.7 vs. 21.7± 2.8 days, p < 0.05), but there were also evident improvements
both in mood and general well-being in the supplemented patients.
On the contrary, in a prospective double-blind RCT performed by Déchelotte et al. [87]
in 114 patients with critical illnesses treated with 0.33 g/kg/day Gln, no significant differ-
ences in LOS nor patient mortality were observed (1.9 vs. 3.8% deaths, p > 0.05), although
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a reduction of the incidence of infectious complications (39 vs. 64%, p < 0.02) was noted.
The decrease of nosocomial infections, such as urinary tract infections (2.3 vs. 16.9%,
p = 0.03) and pneumonia (8 vs. 29%, p = 0.02) were also observed by Grau et al. [100]. This
trial studied the effect of 0.35 g/kg/day Gln in a multicentre, prospective, double-blind,
RCT in 502 patients admitted to the UCI. In another double-blind RCT performed by
Estívariz et al. [91] in 63 people undergoing surgery and in ICU, patients were supple-
mented with 0.34 g/kg/day Gln and a lessening of nosocomial infections was observed
(13 vs. 36 cases, p < 0.03). Kłek et al. [84] also reported a decrease in postoperative compli-
cations (23.3 vs. 36.6%, p < 0.05) and LOS (14.8 vs. 16.4 days, p < 0.05) in an RCT performed
in 69 patients undergoing surgery supplemented with 0.27 g/kg/day Gln for 12 days.
On the contrary, a double-blind RCT conducted by Andrews et al. [98], patients
supplemented with 0.2 g/kg/day Gln for at least 5 days, neither showed a significant
improvement in the incidence of infections nor patient mortality compared to the control
group (p > 0.05).
The effect of glutamine on LOS was reported by 21 studies involving 1042 participants.
According to the meta-analysis, glutamine supplementation has shown to significantly de-
crease the days of hospitalization (MD:−2.65, 95% CI:−3.10,−2.21, p < 0.00001, Figure 10).
Exhibiting a high heterogeneity among studies (I2 = 84%). Nevertheless, not all the studies
showed a significant effect on this parameter. This is the case of the following studies:
Wischmeyer et al. [78] (MD: 1.00, 95% CI:−6.51, 8.51), Ockenga et al. [80] (MD: 0.50, 95% CI:
−5.00, 6.00), Zhou et al. [82] (MD: −4.00, 95% CI: −8.87, 0.87), Fuentes-Orozco et al. [81]
(MD: −0.17, 95% CI: −5.63, 5.29), Kiek et al. [84] (MD: −1.80, 95% CI: −5.68, 2.08),
Şahin et al. [88] (MD: −2.20, 95% CI: −4.78, 0.38), Fuentes-Orozco et al. [93] (MD: 3.59,
95% CI: −3.47, 10.65), Engel et al. [63] (MD: 0.40, 95% CI: −0.55, 1.35), Çekmen et al. [99]
(MD: −8.20, 95% CI: −17.04, 0.64).
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Overall data from 11 studies involving 696 participants (340 and 356 in the study and
control group respectively) were evaluated. Patient mortality occurred less frequently in
the glutamine-supplemented group than in controls (46 (13.53%) vs. (89 (25%) participants).
The odds ratio was 0.48 (95% CI: 0.32, 0.72, p = 0.0004, Figure 11), and heterogeneity among
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studies was 14%. The number needed to treat was 10. In other words, 10 patients would
need to receive glutamine supplementation to prevent an additional fatality.
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3.4.4. Lactulose/Mannitol Ratio
Zhou et al. [82] observed a decrease in the intestinal permeability in the study group
(0.021 ± 0.006 vs. 0.025 ± 0.007 L/M ratio, p = 0.115). These data are in agreement with
those by Jiang et al. [73] who also noted a decrease in intestinal permeability, assessed by
lactulose/mannitol excretion rate ratio (L/M ratio) (0.097 ± 0.063 vs. 0.132 ± 0.081 L/M
ratio, p = 0.02). Similar results were reported by Xu et al. [103] who also noted the reduction
of L/M (p < 0.05).
Five studies involving 210 participants reported data on intestinal permeability, as-
sessed by lactulose/mannitol ratio. L/M significantly decreased in those participants
supplemented with glutamine (MD: −0.01, 95% CI: −0.02, −0.01, p < 0.00001, Figure 12).
The heterogeneity given by I2 was 97%.
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3.4.5. C-Reactive Protein
Çekmen et al. [99] observed a trend to the reduction in CRP (57.65 ± 41.81 vs.
82.87 ± 69.41 mg/L, p = 0.32) compared to the control group. Nevertheless, these results
did not reach significance.
A double-blind RCT performed by Lu et al. [101] on 50 patients, suffering from
gastrointestinal cancer and undergoing surgery, supplemented with 0.3 g/kg/day Gln;
reported a significant reduction in CRP serum level (16.7 ± 11.8 vs. 35.2 ± 24.8 mg/dL,
p = 0.013). Besides, in the control group, there were noted 4 cases of infectious complications
while none were observed in the study group (p = 0.037). The reduction in CRP (p < 0.01)
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was also observed by Wischmeyer et al. [78] in a double-blind RCT in 31 patients with
severe burns, supplemented with 0.57 g/kg/day L-Gln for at least 7 days via parenteral
feeding. Ockenga et al. [80], as well as Dong et al. [92] also reported a significant decrease
in CRP (30 ± 42 vs. 34 ± 51, p < 0.01), (69 ± 19 vs. 99 ± 44, p = 0.01)
Yeh et al. [94] noted the CRP lessening (p = 0.012) in an RCT in 70 patients undergoing
surgery for 7 days. Another RCT performed by Cai et al. [89] suggested a pronounced
decrease of CRP (25.8 ± 4.9 vs. 15.6 ± 4.2 mg/dL, p = 0.001) after performing an RCT sup-
plementing 110 patients suffering from a critical illness with 0.19 g/kg/day Gln for 14 days.
Besides, it was also suggested a decrease in the illness severity, assessed by APACHE II
scores (10.35 ± 4.35 vs. 17.75 ± 4.46, p = 0.001). Richard et al. [104] supplemented patients
before and after surgery and also observed a significant decrease in CRP (44 ± 35 vs.
69 ± 19 mg/L, p = 0.028)
Eleven studies reported the effect of glutamine supplementation on CRP levels. Al-
though, individually, 5 studies data did not reach statistical significance [63,80,87,88,99],
the overall effect showed the reduction of CRP levels after supplementation (MD: −1.10,
95% CI: −1.26, −0.93, p < 0.00001, Figure 13). The heterogeneity among studies was 82%.
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3.4.6. Cytokines 
Quan et al. [97] observed a significant reduction of IL-6 (6.95 ± 5.08 vs. 12.88 ± 3.85 
ng/L, p < 0.05) when 20 patients undergoing abdominal surgery were supplemented with 
0.28 g/kg/day Gln for 4 days in a multicentre double-blind RCT. The reduction in IL-6 was 
also reported by Lu et al. [101] (19.2 ± 9.8 vs. 34.7 ± 18.7 pg/mL, p = 0.01). 
On the other hand, Xu et al. [103] noted a reduction in TNFα levels (p = 0.01) in an 
RCT in 80 patients supplemented with glutamine administered via early enteral nutrition. 
O’Riordain et al. [69] performed a double-blind RCT in 22 patients undergoing sur-
gery and supplemented with 0.18 g/kg/day Gln in the form of glycyl-glutamine, for 5 days. 
This trial measured the IL-6 and TNFα levels. Nevertheless, the data failed to reach sig-
nificance (p = 0.27 and p > 0.05, respectively). The lack of significance regarding the pro-
duction of IL-6 was also observed in a double-blind RCT performed by De Beaux et al. 
[70] in 14 patients suffering from critical illnesses. 
Five and four studies reported data on IL-6 and TNFα levels, respectively. Both pa-
rameters showed a significant reduction after glutamine supplementation for IL-6 levels 
(MD: −5.78, 95% CI: −8.71, −2.86, I2 = 74, p = 0.0001) and for TNFα levels (MD: −8.15, 95% 
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3.4.6. Cytokines
Quan et al. [97] observ d a significant reduction of IL-6 (6.95± 5.08 vs. 12.88 ± 3.85 ng/L,
p < 0.05) when 20 patients undergoin abdominal surgery were supplemented with
0.28 g/kg/ ay l for 4 days in a multicentre double-blind RCT. The reduction in IL-
6 was also reported by Lu et al. [101] (19.2 ± 9.8 vs. 34.7 ± 18.7 pg/mL, p = 0.01).
On the other hand, Xu et al. [103] noted a reduction in TNFα levels (p = 0.01) in an
RCT in 80 patients supplemented with glutamine administered via early enteral nutrition.
O’Riordain et al. [69] performed a double-blind RCT in 22 patients undergoing surgery
and supplemented with 0.18 g/kg/day Gln in the form of glycyl-glutamine, for 5 days. This
trial measured the IL-6 and TNFα levels. Nevertheless, the data failed to reach significance
(p = 0.27 and p > 0.05, respectively). The lack of significance regarding the production
of IL-6 was also observed in a double-blind RCT performed by De Beaux et al. [70] in
14 patients suffering from critical illnesses.
Five and four studies reported data on IL-6 and TNFα levels, respectively. Both
parameters showed a significant reduction after glutamine supplementation for IL-6 levels
(MD: −5.78, 95% CI: −8.71, −2.86, I2 = 74, p = 0.0001) and for TNFα levels (MD: −8.15,
95% CI: −9.34, −6.96, I2 = 97, p < 0.00001, Figure 14a,b). This occurred despite the lack of
significance shown by 2 different studies in both parameters. For IL-6 levels this was the
case of Mertes et al. [75] (MD: 24.00, 95% CI: −78.69, 126.69) and Lin et al. [85] (MD: −4.5,
95% CI: −9.96, 0.96) while for TNFα levels they were Mertes et al. [75] (MD: 7.00, 95% CI:
−0.69, 14.69) and Lu et al. [101] MD: −2.60, 95% CI: −9.78, 4.58).
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3.4.7. T-Cell Lymphocytes
Karwowska et al. [76] performed an RTC and studied the effect of glutamine in the
immune system by the increase of T-cells, particularly, CD4 and CD8 lymphocytes, IgA,
IgG in well-nourished male patients undergoing abdominal surgery, sup lemented with
0.202 g/kg/ l . i ifi t i i the total counts of lymphocytes (p = 0.0 5),
CD4 lymphocytes (p = 0. 5), CD8 lymphocytes (p = 0. 1), IgA (p = 0. 05) and IgG (p = 0.02)
were observed. et al. [84] also reported a incr ase in T-cell lymphocytes in the
grou supplemented with Gln. Nevertheless, this measurement did not reach s gnificance
(p > 0.05).
Asprer et al. [95] also noticed an increase in T-cell ymphocytes count (p = 0. 49) in a
prospective RCT performed in 34 patients supplemented with 0.3 g/kg/day Gln for 5 days
before surgery. This data is in agreement with Ockenga et al. [80], who also reported an
increase in lymphocytes (1.7 ± 0.7 vs. 1.5 ± 0.4, p < 0.01). Similar results were reported by
Cai et al. [89] (1.91 ± 0.3 vs. 1.35 ± . 109/L, p = .001) and Dong et al. [92] (p < .01).
On the contrary, O’Riordain et al. [69] reported a significant increase in the synthesi
of T-cell DNA, measured with the tritiated thymidine index, compared to the control group
(p < 0.05).
In a double-blind RCT carried out by Fuentes- rozco et al. [81] for 10 days, on
33 patients with secondary peritonitis, supplemented with 0.26 g/kg/day Gln, it was also
suggested an increase in T-cells levels, including, their subpopulations, CD4 and CD8.
However, no significant difference was reached (p > 0.05).
Regarding the effect of glutamine supplementation on T-cell lymphocytes, there is
contradictory evidence in the literature.
However, fourteen studies involving 540 participants (315 and 312 in the experimental
and control group, respectively) showed that glutamine supplementation might increase
T-cell lymphocytes levels. Nevertheless, the data analysis showed a lack of significance in
the measured parameter (MD: −0.16, 95% CI: −0.33, 0.01, I2 = 93, p = 0.07, Figure 15).
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Based on the findings of the systematic review, arginine supplementation resulted in
greater collagen formation assessed by hydroxyproline level (p < 0.00001). The deposition
of collagen could in part be enhanced by T-cell-mediated immune function since they
recruit and activate fibroblasts which play a key role in wound repair [105].
The effect of arginine supplementation on T-cell lymphocytes and nitrogen balance
was reported in some studies. Nevertheless, its beneficial effect was not always ob-
served [66]. A reason that could explain this outcome may be the lack of additional
calories administered either parentally or enterally, which attenuates or even eliminates
the pharmaceutical effect of arginine [18,19]. This occurs because around 40% of arginine
is catabolized in a single pass in the small intestine, by the type II arginase, and to a much
lesser extent, by NO synthase [106]. Indeed, Castillo et al. [107] stated that only 0.34% of
the arginine intake absorbed in the splanchnic bed is used to synthesize NO, contributing
to 16% of the daily production of NO. Attempts to meet energy requirements were done in
most trials, with a minimum of 120 kcal/day in the trial conducted by Debats et al. [65]
and a maximum of 2474 kcal/day in the study performed by Langkamp-Henken et al. [60].
Some studies did not show a significant increase or decrease in lymphocyte proliferation
and nitrogen balance, respectively [60]. The explanation for this could be the timing of
the measurements. Since the elimination of half-life of an oral load of arginine is about
80 min [108].
4.2. Glutamine
Regarding glutamine supplementation, the greater cumulative nitrogen balance noted
in some of these st dies explains the use f glutamine by the body as a substrate for
the synthesis of NO. Improv d nitrogen r tenti n is associated with a shorter length of
hospital stay, and high levels of IL-6 are associated with infect ons and mortality. Th lower
pr duction of proinflammatory cytokines might also be explained due to the decrease in
intestinal permeability [48]. Therefore, an increase in t e nitrog n ba nce and declin of
IL-6 may explain why in many studies, there was a reduction in the len th of hospit l-
izatio and patient mortality observed [61]. However, the decrease in mortality was not
always significant in this review, hence not fully agreeing with the review conducted by
Bollhalder et al. [53].
In a prospective double-blind RCT performed by Déchelotte et al. [87] in 114 patients
with critical illnesses, no significant differences in LOS nor patient mortality were observed
(1.9 vs. 3.8% deaths, p > 0.05), and even if there was an improvement in the nitrogen
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balance, this variation did not reach significance (−2.44 ± 8.6 vs. −4.4 ± 13.2, p > 0.05). In
this case, the benefits of supplementation may have been due to the decrease in intestinal
permeability [40,44,46], resulting thus, in the reduction of the incidence of infectious com-
plications (39 vs. 64%, p < 0.02). The decrease of the infectious complications (4 vs. 12 cases,
p < 0.005) could be possibly influenced by the increase of the nitrogen balance (12 ± 2 vs.
5 ± 1 g N, p < 0.05), as well as the levels of IgA (335.7 ± 31.44 vs. 357.81 ± 83.61 mg/dL,
p = 0.029) and IgG between intervention and the control group [81].
Şahin et al. [88] reported a lessening in CRP in both groups, although the decrease was
more pronounced in the study group (−38 vs. 18.6%, p = 0.00 and p = 0.01, respectively).
However, these values were still higher than usual and a reason for this could be the
presence of fewer leukocytes, and inflammation. In this trial, there was a reduction in
LOS (14.2 ± 4.4 vs. 16.4 ± 3.9 days, p > 0.05) and complication rates (10 vs. 40%, p < 0.05)
which may be due to an increase in CD4 and CD8 lymphocytes, although the latter failed
to reach significance (p > 0.05). The increase in T-cell lymphocytes was also reported in
other studies [80,83,87]. Nevertheless, in line with the latter, these measurements did not
reach significance (p > 0.05).
Fuentes-Orozco et al. [93] reported a significant increase of nitrogen balance (p = 0.04),
total lymphocytes count (p = 0.04), CD4 lymphocytes (p = 0.03), CD8 lymphocytes (p = 0.03),
IgA (p = 0.01) and IL-10 (p = 0.02), an anti-inflammatory cytokine, were observed, along
with a significant decrease of CRP (0.005) and IL-6 (p = 0.03). These data might explain the
decrease in the incidence of infectious complications in the supplemented group (68.4%)
when compared to the control group (31.6%, p = 0.03), as well as the mortality (9 vs. 22.7%),
although the latter failed to reach significance (p = 0.20).
According to a review conducted by Novak et al. [54], the minimum concentration
of glutamine to obtain positive clinical outcomes is 0.2 g/kg/day Gln, corresponding to
0.303 g/kg/day Ala-Gln dipeptide. Nevertheless, this amount could be raised to 20 g/day
Gln according to Wischmeyer et al. [78], Heyland et al. [109] and García-De-Lorenzo [110].
Regarding Gln toxicity, Garlick [111] suggested that doses as high as 50–60 g/day Gln
for several weeks were safe and showed no adverse effect. The use of a lower amount of
glutamine could in part explain the lack of significance in the reduction of cytokines levels
in some studies [69]. In the study by Engel et al. [63], dose requirements according to the
previous studies [54,78,109,110] were met. In this case, a reason to explain these results
may be the short time used for supplementation (3 days) rather than the dose used.
The form of supplementation used might also affect the outcome, even if the minimum
amount of glutamine is given. This could be explained since glutamine in the form of
L-Gln presents much lower stability than Ala-Gln dipeptide [78]. In addition, the effect of
glutamine may also vary depending on whether it is given postoperatively and parenterally,
and whether it is given preoperatively [95,104] and enterally [103], respectively. The
observed beneficial effect on L/M ratio and TNFα levels was more pronounced when
glutamine was administered by the enteral route. However, since the authors do not
specify the amount of the administered glutamine, it is difficult to determine whether
this observation is dose dependent or is due to the method of administration being the
enteral route.
The shortest study [63] supplemented patients for just 3 days with 0.5 g/kg/day
Gln in a double-blind RCT. In this trial, no significant differences were found in total
lymphocytes count (p > 0.05), IL-6 levels (p < 0.05), LOS (2.6 ± 2.0 vs. 2.0 ± 1.7, p = 0.44),
CRP (p = 0.72), IL-8 (p > 0.05) or TNFα (p > 0.05). This might suggest that a minimum
length of 5 days is needed to achieve an effect in at least one of the parameters related to
healing [69].
Besides, according to Morlion et al. [71], glutamine supplementation may also have a
positive effect on the patient’s mood and general well-being. A reason for this could be the
role of Gln as a neurotransmitter [112,113] as its depletion has been shown to cause mood
disorders such as depression [113–115].
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Therefore, it would be useful to measure this parameter in future studies to corroborate
this effect.
5. Limitations of the Review
In the case of arginine, five studies were included in the meta-analysis. However, it
was not possible to assess the effect of arginine supplementation on nitrogen balance and
T-cell lymphocytes due to the lack of studies reporting these data. Besides, the studies had
relatively small sample sizes. Therefore, more studies are required in this area of research.
Besides, the high heterogeneity of the studies of both amino acids might have also affected
the results of the meta-analysis.
6. Conclusions
This systematic review and meta-analysis have demonstrated that supplementation
with either arginine and glutamine can positively influence wound healing or parameters
related to healing including LOS and mortality. The effect of arginine supplementation was
significant in relation to hydroxyproline content (p < 0.00001), while glutamine supplemen-
tation had significant effect on nitrogen balance (p < 0.0001), patient mortality (p = 0.0004),
L/M ratio (p < 0.00001), LOS (p < 0.00001), CRP (p < 0.00001), IL-6 levels (p = 0.0001) and
TNFα levels (p < 0.00001). However, the effect of glutamine supplementation on T-cell
lymphocytes failed to reach significance (p = 0.07).
Author Contributions: Writing—original draft preparation, E.A.-L.; Writing—review and editing,
N.Z.; O.O.; Supervision, N.Z.; Funding, M.J.S. and T.K. All authors have read and agreed to the
published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare that there are no conflict of interest.
References
1. Armstrong, G.D.; Meyr, A.J. Basic Principles of Wound Management. Atlas Small Anim. Wound Manag. Reconstr. Surg. 2018,
4, 33–52.
2. The Editors of Encyclopaedia Britannica. Encycl. Br. 2019. Available online: https://www.britannica.com/science/wound
(accessed on 11 June 2021).
3. Gonzalez, A.C.D.O.; Andrade, Z.D.A.; Costa, T.F.; Medrado, A.R.A.P. Wound healing-A literature review. An. Bras. Dermatol.
2016, 91, 614–620. [CrossRef] [PubMed]
4. Orr, J.W.; Taylor, P.T. Wound healing. In Complications in Gynecological Surgery: Prevention, Recognition, and Management; J. B.
Lippincott & Co.: Philadelphia, PA, USA, 2018.
5. Skover, G.R. Cellular and biochemical dynamics of wound repair. Wound environment in collagen regeneration. Clin. Podiatr.
Med. Surg. 1991, 8, 723–756. [PubMed]
6. Lawrence, W.T. Physiology of the acute wound. Clin. Plast. Surg. 1998, 25, 321–340. [CrossRef]
7. Hart, J. Inflammation. 1: Its role in the healing of acute wounds. J. Wound Care 2002, 11, 205–209. [CrossRef]
8. Toy, L.W. Matrix metalloproteinases: Their function in tissue repair. J. Wound Care 2005, 14, 20–22. [CrossRef]
9. Bacci, S. Cutaneous wound healing: Cellular mechanisms and therapies (an update). Med. Res. Arch. 2019, 7. [CrossRef]
10. Bunman, S.; Dumavibhat, N.; Chatthanawaree, W.; Ntalapaporn, S.; Thuwachaosuan, T.; Thongchuan, C. Burn Wound Healing:
Pathophysiology and Current Management of Burn Injury. Bangkok Med. J. 2017, 13, 91–98. [CrossRef]
11. Adzick, N.S.; Longaker, M.T. Scarless fetal healing: Therapeutic implications. Ann. Surg. 1992, 215, 3–7. [CrossRef]
12. Russell, L. Understanding physiology of wound healing and how dressings help. Br. J. Nurs. 2000, 9. [CrossRef] [PubMed]
13. Zomer, H.D.; Trentin, A.G. Skin wound healing in humans and mice: Challenges in translational research. J. Dermatol. Sci. 2018,
90, 3–12. [CrossRef]
14. Baum, C.L.; Arpey, C.J. Normal cutaneous wound healing: Clinical correlation with cellular and molecular events. Dermatol.
Surg. 2005, 31, 686. [CrossRef]
15. Liu, Z.J.; Velazquez, O.C. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid. Redox Signal.
2008, 10, 1869–1882. [CrossRef] [PubMed]
16. Masre, S.F.; Yip, G.W.; Sirajudeen, K.N.S.; Ghazali, F.C. Quantitative analysis of sulphated glycosaminoglycans content of
Malaysian sea cucumber Stichopus hermanni and Stichopus vastus. Nat. Prod. Res. 2012, 26, 684–689. [CrossRef] [PubMed]
17. Singer, A.J.; Clark, R.A.F. Cutaneous Wound Healing. N. Engl. J. Med. 1999, 341, 738–746. [CrossRef] [PubMed]
Nutrients 2021, 13, 2498 23 of 26
18. Leigh, B.; Desneves, K.; Rafferty, J.; Pearce, L.; King, S.; Woodward, M.C.; Brown, D.; Martin, R.; Crowe, T.C. The effect of different
doses of an arginine-containing supplement on the healing of pressure ulcers. J. Wound Care 2012, 21, 150–156. [CrossRef]
19. McNeal, C.J.; Meininger, C.J.; Wilborn, C.D.; Tekwe, C.D.; Wu, G. Safety of dietary supplementation with arginine in adult
humans. Amino Acids 2018, 50, 1215–1229. [CrossRef]
20. Russell, L. Nutritional status in wound healing. Clinical 2001, 10, S42–S49.
21. Arnold, M.; Barbul, A. Nutrition and wound healing. Plast. Reconstr. Surg. 2006, 117, 42–58. [CrossRef]
22. Witte, M.B.; Barbul, A. Arginine physiology and its implication for wound healing. Wound Repair Regen. 2003, 11, 419–423.
[CrossRef]
23. Campos, A.C.L.; Groth, A.K.; Branco, A.B. Assessment and nutritional aspects of wound healing. Curr. Opin. Clin. Nutr. Metab.
Care 2008, 11, 281–288. [CrossRef]
24. Shepherd, A.A. Nutrition for optimum wound healing. Nurs. Stand. 2003, 18, 55–58. [CrossRef] [PubMed]
25. Tong, B.; Barbul, A. Cellular and Physiological Effects of Arginine. Mini-Reviews Med. Chem. 2004, 4, 823–832. [CrossRef]
[PubMed]
26. Malone-Povolny, M.J.; Maloney, S.E.; Schoenfisch, M.H. Nitric Oxide Therapy for Diabetic Wound Healing. Adv. Healthc. Mater.
2019, 8. [CrossRef] [PubMed]
27. Allan Palmer, T.E.; Griffiths, R.D.; Jones, C. Effect of parenteral l-glutamine on muscle in the very severely Ill. Nutrition 1996, 12,
316–320. [CrossRef]
28. Labow, B.I.; Souba, W.W. Glutamine. World J. Surg. 2000, 24, 1503–1513. [CrossRef]
29. Melis, G.C.; Ter Wengel, N.; Boelens, P.G.; Van Leeuwen, P.A.M. Glutamine: Recent developments in research on the clinical
significance of glutamine. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 59–70. [CrossRef]
30. Parry-Billings, M.; Baigrie, R.J.; Lamont, P.M.; Morris, P.J.; Newsholme, E.A. Effects of Major and Minor Surgery on Plasma
Glutamine and Cytokine Levels. Arch. Surg. 1992, 127, 1237–1240. [CrossRef]
31. Field, C.J.; Johnson, I.; Pratt, V.C. Glutamine and arginine: Immunonutrients for improved health. Med. Sci. Sports Exerc. 2000, 32.
[CrossRef]
32. Murphy, C.; Newsholme, P. Importance of glutamine macrophages and human monocytes to L-arginine biosynthesis and rates of
nitrite or urea production. Clin. Sci. 1998, 95, 397–407. [CrossRef]
33. Newsholme, P. Glutamine Metabolism: Nutritional and Clinical Significance Why Is L-Glutamine Metabolism Important to Cells
of the Immune System in Health, Postinjury, Surgery or Infection? J. Nutr. 2001, 131, 2515–2522. [CrossRef]
34. Wu, G.; Brosnan, J.T. Macrophages can convert citrulline into arginine. Biochem. J. 1992, 281, 45–48. [CrossRef] [PubMed]
35. Coëffier, M.; Claeyssens, S.; Hecketsweiler, B.; Lavoinne, A.; Ducrotté, P.; Déchelotte, P. Enteral glutamine stimulates protein
synthesis and decreases ubiquitin mRNA level in human gut mucosa. Am. J. Physiol.-Gastrointest. Liver Physiol. 2003, 285.
[CrossRef] [PubMed]
36. Le Bacquer, O.; Nazih, H.; Hervé Blottiè, R.E.; Meynial-Denis, D.; Laboisse, C.; Darmaun, D. Effects of glutamine deprivation on
protein synthesis in a model of human enterocytes in culture. Am. J. Physiol.-Gastrointest. Liver Physiol. 2001, 281. [CrossRef]
[PubMed]
37. O’Dwyer, S.T.; Smith, R.J.; Hwang, T.L.; Wilmore, D.W. Maintenance of Small Bowel Mucosa with Glutamine-Enriched Parenteral
Nutrition. J. Parenter. Enter. Nutr. 1989, 13, 579–585. [CrossRef] [PubMed]
38. Souba, W.W.; Klimberg, V.S.; Plumley, D.A.; Salloum, R.M.; Flynn, T.C.; Bland, K.I.; Copeland, E.M. The role of glutamine
in maintaining a healthy gut and supporting the metabolic response to injury and infection. J. Surg. Res. 1990, 48, 383–391.
[CrossRef]
39. Xue, G.D.; Barekatain, R.; Wu, S.B.; Choct, M.; Swick, R.A. Dietary L-glutamine supplementation improves growth performance,
gut morphology, and serum biochemical indices of broiler chickens during necrotic enteritis challenge. Poult. Sci. 2018, 97,
1334–1341. [CrossRef]
40. De-Souza, D.A.; Greene, L.J. Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine. Crit. Care
Med. 2005, 33, 1125–1135. [CrossRef]
41. Fukatsu, K.; Kudsk, K.A.; Zarzaur, B.L.; Wu, Y.; Hanna, M.K.; DeWitt, R.C. TPN decreases IL-4 and IL-10 mRNA expression in
lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Shock
2001, 15, 318–322. [CrossRef]
42. Gianotti, L.; Alexander, J.W.; Gennari, R.; Pyles, T.; Babcock, G.F. Oral glutamine decreases bacterial translocation and improves
survival in experimental gut-origin sepsis. J. Parenter. Enter. Nutr. 1995, 19, 69–74. [CrossRef] [PubMed]
43. Lai, Y.N.; Yeh, S.L.; Lin, M.T.; Shang, H.F.; Yeh, C.L.; Chen, W.J. Glutamine supplementation enhances mucosal immunity in rats
with Gut-Derived sepsis. Nutrition 2004, 20, 286–291. [CrossRef] [PubMed]
44. Van der Hulst, R.R.W.J.; von Meyenfeldt, M.F.; Deutz, N.E.P.; Soeters, P.B.; Brummer, R.J.M.; von Kreel, B.K.; Arends, J.W.
Glutamine and the preservation of gut integrity. Lancet 1993, 341, 1363–1365. [CrossRef]
45. Wischmeyer, P.E.; Riehm, J.; Singleton, K.D.; Ren, H.; Musch, M.W.; Kahana, M.; Chang, E.B. Glutamine attenuates tumor necrosis
factor-α release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. Nutrition 2003, 19, 1–6.
[CrossRef]
Nutrients 2021, 13, 2498 24 of 26
46. Zhou, Y.P.; Jiang, Z.M.; Sun, Y.H.; Wang, X.R.; Ma, E.L.; Wilmore, D. The effect of supplemental enteral glutamine on plasma
levels, gut function, and outcome in severe burns: A randomized, double-blind, controlled clinical trial. J. Parenter. Enter. Nutr.
2003, 27, 241–245. [CrossRef]
47. Ameho, C.K.; Adjei, A.A.; Harrison, E.K.; Takeshita, K.; Morioka, T.; Arakaki, Y.; Ito, E.; Suzuki, I.; Kulkarni, A.D.;
Kawajiri, A.; et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor α
production in trinitrobenzene sulphonic acid induced colitis. Gut 1997, 41, 487–493. [CrossRef]
48. Spindler-Vesel, A.; Wraber, B.; Vovk, I.; Kompan, L. Intestinal permeability and cytokine inflammatory response in multiply
injured patients. J. Interf. Cytokine Res. 2006, 26, 771–776. [CrossRef]
49. Johnson, B.Z.; Stevenson, A.W.; Prêle, C.M.; Fear, M.W.; Wood, F.M. The role of IL-6 in skin fibrosis and cutaneous wound healing.
Biomedicines 2020, 8, 101. [CrossRef]
50. Sproston, N.R.; Ashworth, J.J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 2018, 9, 1–11.
[CrossRef]
51. Vehe, K.L.; Brown, R.O.; Kuhl, D.A.; Boucher, B.A.; Lutherou, R.W.; Kudsk, K.A. The prognostic inflammatory and nutritional
index in traumatized patients receiving enteral nutrition support. J. Am. Coll. Nutr. 1991, 10, 355–363. [CrossRef]
52. Yeligar, S.M.; Harris, F.L.; Hart, C.M.; Brown, L.A.S. Glutathione attenuates ethanol-induced alveolar macrophage oxidative stress
and dysfunction by downregulating NADPH oxidases. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2014, 306. [CrossRef]
53. Bollhalder, L.; Pfeil, A.M.; Tomonaga, Y.; Schwenkglenks, M. A systematic literature review and meta-analysis of randomized
clinical trials of parenteral glutamine supplementation. Clin. Nutr. 2013, 32, 213–223. [CrossRef] [PubMed]
54. Novak, F.; Heyland, D.K.; Avenell, A.; Drover, J.W.; Su, X. Glutamine supplementation in serious illness: A systematic review of
the evidence. Crit. Care Med. 2002, 30, 2022–2029. [CrossRef] [PubMed]
55. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; Estarli, M.;
Barrera, E.S.A.; et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
Rev. Esp. Nutr. Hum. Diet. 2016, 4, 1. [CrossRef] [PubMed]
56. Ankit Rohatgi WebPlotDigitizer 4.4. Available online: https://automeris.io/WebPlotDigitizer (accessed on 11 June 2021).
57. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane Handbook for Systematic Reviews of
Interventions; John Wiley & Sons: Chichester, UK, 2019; ISBN 9781119536604.
58. The Nordic Cochrane Centre. Review Manager, Version 5.4; The Cochrane Collaboration: Copenhagen, Denmark, 2020.
59. Barbul, A.; Lazarou, S.A.; Efron, D.T.; Wasserkrug, H.L.; Efron, G. Arginine enhances wound healing and lymphocyte immune
responses in humans. In Proceedings of the Surgery; Mosby Inc.: St. Louis, MO, USA, 1990; Volume 108, pp. 331–337.
60. Langkamp-Henken, B.; Herrlinger-Garcia, K.A.; Stechmiller, J.K.; Nickerson-Troy, J.A.; Lewis, B.; Moffatt, L. Arginine supplemen-
tation is well tolerated but does not enhance mitogen-induced lymphocyte proliferation in elderly nursing home residents with
pressure ulcers. J. Parenter. Enter. Nutr. 2000, 24, 280–287. [CrossRef]
61. Goeters, C.; Wenn, A.; Mertes, N.; Wempe, C.; Van Aken, H.; Stehle, P.; Bone, H.-G. Parenteral L-alanyl-L-glutamine improves
6-month outcome in critically ill patients. Crit. Care Med. 2002, 30, 2032–2037. [CrossRef]
62. He, X.L.; Ma, Q.J.; Lu, J.G.; Chu, Y.K.; Du, X.L. Effect of total parenteral nutrition (TPN) with and without glutamine dipeptide
supplementation on outcome in severe acute pancreatitis (SAP). Clin. Nutr. Suppl. 2004, 1, 43–47. [CrossRef]
63. Engel, J.M.; Pitz, S.; Mühling, J.; Menges, T.; Martens, F.; Kwapisz, M.; Hempelmann, G. Role of glutamine administration on
T-cell derived inflammatory response after cardiopulmonary bypass. Clin. Nutr. 2009, 28, 15–20. [CrossRef]
64. Nussbaum, M.S. Arginine Stimulates Wound Healing and Immune Function in Elderly Human Beings. J. Parenter. Enter. Nutr.
1994, 18, 194. [CrossRef]
65. Debats, I.B.J.G.; Koeneman, M.M.; Booi, D.I.; Bekers, O.; Van Der Hulst, R.R.W.J. Intravenous arginine and human skin graft
donor site healing: A randomized controlled trial. Burns 2011, 37, 420–426. [CrossRef]
66. Sigal, R.K.; Shou, J.; Daly, J.M. Parenteral arginine infusion in humans: Nutrient substrate or pharmacologic agent? J. Parenter.
Enter. Nutr. 1992, 16, 423–428. [CrossRef] [PubMed]
67. Gamelli, R.L.; He, L.-K. Incisional Wound Healing: Model and Analysis of Wound Breaking Strength. In Wound Healing; Humana
Press: Clifton, NJ, USA, 2003; pp. 037–054.
68. Fürst, P. Old and new substrates in clinical nutrition. J. Nutr. 1998, 128, 789–796. [CrossRef] [PubMed]
69. O’Riordain, M.G.; Fearon, K.C.H.; Ross, J.A.; Rogers, P.; Falconer, J.S.; Bartolo, D.C.C.; Garden, O.J.; Carter, D.C. Glutamine-
supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection.
Ann. Surg. 1994, 220, 212–221. [CrossRef] [PubMed]
70. De Beaux, A.C.; O’Riordain, M.G.; Ross, J.A.; Jodozi, L.; Carter, D.C.; Fearon, K.C.H. Glutamine-supplemented total parenteral
nutrition reduces blood mononuclear cell interleukin-8 release in severe acute pancreatitis. Nutrition 1998, 14, 261–265. [CrossRef]
71. Morlion, B.J.; Stehle, P.; Wachtler, P.; Siedhoff, H.P.; Köller, M.; König, W.; Fürst, P.; Puchstein, C. Total parenteral nutrition with
glutamine dipeptide after major abdominal surgery: A randomized, double-blind, controlled study. Ann. Surg. 1998, 227, 302–308.
[CrossRef]
72. Jacobi, C.A.; Ordemann, J.; Zuckermann, H.; Döcke, W.; Volk, H.D.; Müller, J.M. Effect of alanyl-glutamine in postoperative total
parenteral nutrition on postoperative immunosuppression and morbidity. Preliminary results of a prospective randomized study.
Langenbecks Arch. Chir. Suppl. Kongressbd. 1998, 115, 605–611.
Nutrients 2021, 13, 2498 25 of 26
73. Jiang, Z.M.; Cao, J.D.; Zhu, X.G.; Zhao, W.X.; Yu, J.C.; Ma, E.L.; Wang, X.R.; Zhu, M.W.; Shu, H.; Liu, Y.W. The impact of
alanyl-glutamine on clinical safety, nitrogen balance, intestinal permeability, and clinical outcome in postoperative patients: A
randomized, double-blind, controlled study of 120 patients. J. Parenter. Enter. Nutr. 1999, 23, S62–S66. [CrossRef] [PubMed]
74. Powell-Tuck, J.; Jamieson, C.P.; Bettany, G.E.A.; Obeid, O.; Fawcett, H.V.; Archer, C.; Murphy, D.L. A double blind, randomised,
controlled trial of glutamine supplementation in parenteral nutrition. Gut 1999, 45, 82–88. [CrossRef]
75. Mertes, N.; Schulzki, C.; Goeters, C.; Winde, G.; Benzing, S.; Kuhn, K.S.; Van Aken, H.; Stehle, P.; Fürst, P. Cost containment
through L-alanyl-L-glutamine supplemented total parenteral nutrition after major abdominal surgery: A prospective randomized
double-blind controlled study. Clin. Nutr. 2000, 19, 395–401. [CrossRef]
76. Karwowska, K.A.; Dworacki, G.; Trybus, M.; Zeromski, J.; Szulc, R. Influence of glutamine-enriched parenteral nutrition on
nitrogen balance and immunologic status in patients undergoing elective aortic aneurysm repair. Nutrition 2001, 17, 475–478.
[CrossRef]
77. Neri, A.; Mariani, F.; Piccolomini, A.; Testa, M.; Vuolo, G.; Di Cosmo, L. Glutamine-supplemented total parenteral nutrition in
major abdominal surgery. Nutrition 2001, 17, 968–969. [CrossRef]
78. Wischmeyer, P.E.; Lynch, J.; Liedel, J.; Wolfson, R.; Riehm, J.; Gottlieb, L.; Kahana, M. Glutamine administration reduces Gram-
negative bacteremia in severely burned patients: A prospective, randomized, double-blind trial versus isonitrogenous control.
Crit. Care Med. 2001, 29, 2075–2080. [CrossRef] [PubMed]
79. Lin, M.T.T.; Kung, S.P.P.; Yeh, S.L.L.; Lin, C.; Lin, T.H.H.; Chen, K.H.H.; Liaw, K.Y.Y.; Lee, P.H.H.; Chang, K.J.J.; Chen, W.J.J. The
effect of glutamine-supplemented total parenteral nutrition on nitrogen economy depends on severity of diseases in surgical
patients. Clin. Nutr. 2002, 21, 213–218. [CrossRef] [PubMed]
80. Ockenga, J.; Borchert, K.; Rifai, K.; Manns, M.P.; Bischoff, S.C. Effect of glutamine-enriched total parenteral nutrition in patients
with acute pancreatitis. Clin. Nutr. 2002, 21, 409–416. [CrossRef] [PubMed]
81. Fuentes-Orozco, C.; Anaya-Prado, R.; González-Ojeda, A.; Arenas-Márquez, H.; Cabrera-Pivaral, C.; Cervantes-Guevara, G.;
Barrera-Zepeda, L.M. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary
peritonitis. Clin. Nutr. 2004, 23, 13–21. [CrossRef]
82. Zhou, Y.P.; Jiang, Z.M.; Sun, Y.H.; He, G.Z.; Shu, H. The effects of supplemental glutamine dipeptide on gut integrity and clinical
outcome after major escharectomy in severe burns: A randomized, double-blind, controlled clinical trial. Clin. Nutr. Suppl. 2004,
1, 55–60. [CrossRef]
83. Quan, Z.F.; Yang, C.; Li, N.; Li, J.S. Effect of glutamine on change in early postoperative intestinal permeability and its relation to
systemic inflammatory response. World J. Gastroenterol. 2004, 10, 1992–1994. [CrossRef]
84. Kłek, S.; Kulig, J.; Szczepanik, A.M.; Jedrys, J.; Kołodziejczyk, P. The clinical value of parenteral immunonutrition in surgical
patients. Acta Chir. Belg. 2005, 105, 175–179. [CrossRef]
85. Lin, M.T.; Kung, S.P.; Yeh, S.L.; Liaw, K.Y.; Wang, M.Y.; Kuo, M.L.; Lee, P.H.; Chen, W.J. Glutamine-supplemented total parenteral
nutrition attenuates plasma interleukin-6 in surgical patients with lower disease severity. World J. Gastroenterol. 2005, 11,
6197–6201. [CrossRef]
86. Yao, G.X.; Xue, X.B.; Jiang, Z.M.; Yang, N.F.; Wilmore, D.W. Effects of perioperative parenteral glutamine-dipeptide supplemen-
tation on plasma endotoxin level, plasma endotoxin inactivation capacity and clinical outcome. Clin. Nutr. 2005, 24, 510–515.
[CrossRef]
87. Déchelotte, P.; Hasselmann, M.; Cynober, L.; Allaouchiche, B.; Coëffier, M.; Hecketsweiler, B.; Merle, V.; Mazerolles, M.; Samba,
D.; Guillou, Y.M.; et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications
and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study. Crit. Care
Med. 2006, 34, 598–604. [CrossRef] [PubMed]
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